Annual report pursuant to Section 13 and 15(d)

Note 10 - Investment in Macrophage Therapeutics, Inc. (Details Textual)

v3.19.1
Note 10 - Investment in Macrophage Therapeutics, Inc. (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 07, 2019
Mar. 11, 2015
Jan. 31, 2017
Jul. 31, 2016
May 31, 2016
Mar. 31, 2015
Dec. 31, 2017
Dec. 31, 2015
Dec. 31, 2018
Aug. 31, 2018
Preferred Stock, Shares Authorized             5,000,000   5,000,000  
Preferred Stock, Par or Stated Value Per Share             $ 0.001   $ 0.001  
Preferred Stock, Shares Issued, Total             0   0  
Derivative Liability, Total             $ 63,000   $ 63,000  
Preferred Convertible Stock, Right to Exchange for Common Shares, Minimum Required Proceeds from Initial Public Offering               $ 50,000,000    
Weighted Average Price Common Stock Percentage               80.00%    
Future Common Stock Conversion Share Price               3.00%    
Reclassification of Funds Invested     $ 200,000       200,000      
Subsequent Event [Member] | Complaint By Dr. Goldberg Against Navidea and MT [Member] | MT [Member]                    
Litigation Case, Number of Shares of Super Voting Common Stock Failed to Issue 23,500,000                  
Common Stock [Member]                    
Reclassification of Funds Invested                  
Dr. Michael Goldberg [Member]                    
Convertible Preferred Stock, Percent of Shares Reserved           40.00%        
Dr. Michael Goldberg [Member] | MT [Member]                    
Payments to Acquire Businesses and Interest in Affiliates, Total       $ 200,000            
Resignation Agreement, Percentage Ownership After Signing                   5.00%
Macrophage Therapeutics [Member]                    
Common Stock Shares Authorized Upon Exercise of Warrants           1,500        
Convertible Preferred Stock Shares Issued Upon Conversion, Per Unit           1        
Common Stock Warrants, Issued Upon Conversion, Per Unit           30        
Macrophage Therapeutics [Member] | Common Stock [Member]                    
Common Stock as Percentage of Common Equity           1.00%        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   300             300  
Platinum [Member] | MT [Member]                    
Payments to Acquire Businesses and Interest in Affiliates, Total       $ 300,000 $ 200,000          
MT [Member]                    
Convertible Preferred Stock, PIK Coupon, Percentage       10.00%            
Convertible Preferred Stock, Conversion Price, Market Cap       $ 500,000,000            
Convertible Preferred Stock [Member]                    
Preferred Stock, Shares Authorized           50        
Preferred Stock, Par or Stated Value Per Share           $ 50,000        
Cumulative Preferred Stock [Member]                    
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total   $ 500,000                
Issuance of Stock and Warrants for Purchase Agreement, Remaining Amount               $ 2,000,000    
Preferred Stock, Fair Value Put Option               113,000    
Future Common Stock Conversion Denominator, Value               $ 50,000    
Cumulative Preferred Stock [Member] | Macrophage Therapeutics [Member]                    
Preferred Stock, Shares Authorized           50        
Preferred Stock, Shares Issued, Total           10        
Preferred Stock, Redemption Price Per Share               $ 58,320